Cytokine Release Syndrome Epidemiology Forecast 2025-2034

Cytokine release syndrome (CRS), also known as cytokine storm or cytokine-associated toxicity, is a severe clinical syndrome characterized by drastic elevation of inflammatory cytokines. This potentially life-threatening condition can be triggered by infections and certain types of immunotherapies. Various studies suggest that 43 to 100% of study patients affected by leukemia or lymphoma, who receive CAR-T cell therapy targeted to CD19, are affected by cytokine release syndrome. The cytokine release syndrome epidemiology forecast indicates that the incidence of CRS is rising due to the increasing use of immunotherapies, particularly CAR-T cell therapy.

Cytokine Release Syndrome Epidemiology Forecast Report Coverage

The “Cytokine Release Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cytokine release syndrome. It projects the future incidence and prevalence rates of cytokine release syndrome cases across various populations. The study covers age and type as major determinants of the cytokine release syndrome population. The report highlights patterns in the prevalence of cytokine release syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on cytokine release syndrome (CRS) epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cytokine Release Syndrome (CRS) Understanding: Disease Overview

In cytokine release syndrome, an individual's immune system aggressively responds to immunotherapy drugs or infection due to the rapid release of a large amount of cytokines in the blood. Cytokine release syndrome is primarily linked to chimeric antigen receptor (CAR)-T cell therapy but is also observed to occur with bispecific T cell engager therapy and monoclonal antibody-based therapy. Cytokine storms can impact multiple organs, with the symptoms ranging from mild (flu-like symptoms) to severe (low blood pressure, high fever, difficulty in breathing, and multi-organ failure).

Cytokine Release Syndrome Epidemiology Perspective

The cytokine release syndrome (CRS) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for the cytokine release syndrome epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. the cytokine release syndrome detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to the systematic literature review published in Hematology, Transfusion and Cell Therapy (2024), a high incidence of cytokine release syndrome was reported in diffuse large B-cell lymphoma (DLBCL) patients receiving CAR T-cell therapy. The study also revealed that CRS affected 67% of the 1193 patients receiving CAR T-cell therapy, with 10% of the patient pool developing Grade 3 CRS and 3% developing Grade 4 CRS.
• Research shows that the occurrence of cytokine release syndrome (CRS) is significantly dependent on the CAR T-cell product used. For instance, studies using lisocabtagenemaraleucel report around 45% of CRS occurrence, whereas treatment with tisagenlecleucel and axicabtageneciloleucel has reported about 63% and 90% CRS occurrence, respectively.
• Various studies suggest that 43% to 100% of study patients with lymphoma or leukemia, who are treated with CAR T-cell therapy targeted to CD19, are affected by cytokine release syndrome.
• A 2023 study on patients with relapsed/refractory multiple myeloma revealed that 119 out of 165 patients (72.1%) receiving Teclistamab (a B-cell maturation antigen × CD3 bispecific antibody) developed cytokine release syndrome.

Country-wise Cytokine Release Syndrome Epidemiology Segment

The cytokine release syndrome epidemiology data and findings for the United States, EU-4, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cytokine release syndrome (CRS) varies significantly between countries due to several factors that influence its prevalence, diagnosis, and management. A higher incidence of this systemic inflammatory response is reported in countries with greater access to advanced treatments such as CAR T-cell therapies and other immunotherapeutic options. Moreover, regions with a higher burden of hematological malignancies also tend to observe more cases of cytokine release syndrome.

A retrospective 2024 study of 2065 CAR T-cell therapy patients in the United States from the 2021 National Inpatient Sample (NIS) found cytokine release syndrome in 59.8% (1235) of cases, with affected patients being older. CRS severity was classified as 33.4% grade 1, 20.8% grade 2, 4.4% grade 3, and 1.7% grade 4, while 1.2% were unspecified.

Cytokine Release Syndrome: Treatment Overview

The treatment of cytokine release syndrome (CRS) involves a combination of supportive care, targeted cytokine release syndrome therapeutics (such as Tocilizumab (IL-6 receptor blocker)), and intensive care if needed. The treatment plan for this systemic inflammatory response also depends on the grade of cytokine release syndrome. For Grade 2 CRS, moderate therapeutic interventions such as fluids or vasopressors for hypotension are sufficient to manage the symptoms. Grade 3 CRS needs aggressive intervention, like high doses or multiple vasopressor drugs for hypotension. In Grade 4 CRS, immunosuppressants and mechanical ventilation are required to manage the condition.

Key Questions Answered

• What are the key findings of cytokine release syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with cytokine release syndrome across the 8 major markets during the forecast period?
• What was the country-wise cytokine release syndrome epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cytokine release syndrome patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cytokine release syndrome during the forecast period of 2025-2034?
• What are the currently available treatments in the cytokine release syndrome market?
• What are the disease risks, signs, symptoms, and unmet needs of cytokine release syndrome?

Scope of the Cytokine Release Syndrome Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cytokine release syndrome based on several factors.
• The Cytokine Release Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The cytokine release syndrome report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.